GSK (GSK) announced the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA, has recommended expanding the approval of Jemperli in combination with chemotherapy for first-line treatment of all adult patients with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy. This would include patients with mismatch repair proficient /microsatellite stable tumours, who represent 70-75% of patients diagnosed with endometrial cancer and who have limited treatment options. The CHMP opinion is one of the final steps prior to a marketing authorisation decision by the European Commission, with an approval decision expected in the first quarter of 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- GSK announces FDA granted BTD for Jemperli
- Relation announces two strategic collaborations with GSK
- GSK says median overall survival not reached in multiple myeloma study
- GSK announces NMPA of China accepted review of NDA for Blenrep
- GSK announces U.S. FDA accepted its submission for use of Nucala in COPD